Akero Therapeutics Inc.

NASDAQ: AKRO · Real-Time Price · USD
49.42
-0.67 (-1.34%)
At close: Aug 15, 2025, 3:04 PM

Akero Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
340.24M 234.21M 249.77M 150.48M
Short-Term Investments
402.84M 315.8M 101.68M 37.77M
Long-Term Investments
54.75M 19.28M n/a n/a
Other Long-Term Assets
n/a n/a 108K 417K
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
27.3M 9.95M n/a n/a
Total Current Assets
770.38M 559.96M 355.17M 193.58M
Property-Plant & Equipment
755K 1.03M 1.29M 1.55M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
55.51M 20.31M 1.4M 1.97M
Total Assets
825.89M 580.27M 356.57M 195.55M
Account Payables
9.03M 7.04M 7.97M 6.71M
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
n/a n/a n/a 205K
Other Current Liabilities
30.44M 1.3M 9.99M 17.46M
Total Current Liabilities
39.75M 19.13M 19.08M 25.13M
Long-Term Debt
35.3M 24.96M 9.54M 1.31M
Other Long-Term Liabilities
194K 54K 305K -1.31M
Total Long-Term Liabilities
36.02M 25.84M 10.93M 1.31M
Total Liabilities
75.77M 44.97M 30.01M 26.44M
Total Debt
36.12M 26.3M 10.95M 1.52M
Common Stock
7K 6K 5K 4K
Retained Earnings
-826.16M -574.1M -422.34M -310.3M
Comprehensive Income
948K 270K 37K -27K
Shareholders Equity
750.11M 535.31M 326.56M 169.11M
Total Investments
457.59M 335.09M 101.68M 37.77M